Members of Synsam’s Group Management sold 42,240 shares to cover tax liabilities arising from the recently ended LTIP 2023 share-based incentive program. A total of 196,114 shares were allotted to these members under the program. Following the divestments, the concerned executives retain a larger holding in Synsam than they held prior to the allotment. These transactions have been reported to the Swedish Financial Supervisory Authority (Finansinspektionen) as required by regulations, and current shareholdings are available at synsamgroup.com. The sales were specifically executed to manage tax costs associated with the share allocation, not for general liquidity or strategic exit purposes.
Synsam AB (publ) repurchased a total of 125,000 own shares between June 8 and June 12, 2026. These transactions form part of a share buy-back program announced on May 28, 2026, with a maximum value of MSEK 200, running from June 1, 2026, until February 26, 2027. The repurchases were executed on Nasdaq Stockholm by DNB Carnegie Investment Bank AB to adjust the company’s capital structure. Following these purchases, Synsam holds 3,059,190 own shares as of June 12, 2026, out of 145,313,746 outstanding shares. Daily volumes averaged 25,000 shares, with weighted average prices ranging from SEK 54.65 to SEK 57.93 per day during the period.
Synsam AB (publ) repurchased a total of 99,445 own shares between June 15 and June 18, 2026. These transactions are part of a share buy-back program announced on May 28, 2026, with a maximum value of MSEK 200, running from June 1, 2026, to February 26, 2027. The repurchases were executed on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ) to adjust the company’s capital structure. Following these purchases, Synsam holds 3,158,635 own shares out of 145,313,746 outstanding shares. Daily volumes ranged from 24,445 to 25,000 shares, with weighted average prices between SEK 57.27 and SEK 58.59.
Synsam AB (publ) repurchased a total of 125,000 own shares between June 22 and June 26, 2026. These transactions occurred on Nasdaq Stockholm via DNB Carnegie Investment Bank AB as part of a share buy-back program announced on May 28, 2026. The program, capped at MSEK 200, runs from June 1, 2026, to February 26, 2027, aiming to adjust the company’s capital structure by reducing share capital in compliance with EU Market Abuse Regulation and Safe Harbour Regulation standards. Daily volumes were 25,000 shares each day, with weighted average prices ranging from SEK 54.255332 to SEK 56.707088. Following these purchases, Synsam holds 3,283,635 own shares out of 145,313,746 outstanding shares.
Synsam AB (publ) repurchased a total of 125,000 own shares between June 29 and July 3, 2026. These transactions form part of a share buy-back program announced on May 28, 2026, with a maximum value of MSEK 200, running from June 1, 2026, to February 26, 2027. The repurchases were executed on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ) in compliance with EU Market Abuse Regulation and Safe Harbour Regulation standards. Following these purchases, Synsam’s holding of own shares as of July 3, 2026, amounts to 3,408,635 shares out of 145,313,746 outstanding shares. The program aims to adjust the company’s capital structure by reducing share capital.
Synsam AB (publ) repurchased a total of 130,000 own shares between July 6 and July 10, 2026, as part of its share buy-back program. The transactions were executed on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ). This activity falls within the maximum MSEK 200 program announced on May 28, 2026, which runs from June 1, 2026, to February 26, 2027, aiming to adjust the company’s capital structure. Following these purchases, Synsam held 3,538,635 own shares as of July 10, 2026, out of 145,313,746 outstanding shares. Daily volumes ranged from 25,000 to 30,000 shares, with weighted average prices between SEK 55.55 and SEK 56.78.
Synsam AB (publ) repurchased a total of 100,000 own shares between July 13 and July 17, 2026. These transactions form part of a share buy-back program announced on May 28, 2026, with a maximum value of MSEK 200, running from June 1, 2026, to February 26, 2027. The purpose is to adjust the company’s capital structure by reducing share capital. Repurchases occurred daily except July 16, executed on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ). Following these purchases, Synsam holds 3,638,635 own shares as of July 17, 2026, out of 145,313,746 outstanding shares.
Synsam AB (publ) repurchased a total of 50,000 own shares between July 20 and July 24, 2026, as part of its share buy-back program. The transactions occurred on Nasdaq Stockholm via DNB Carnegie Investment Bank AB (publ), with 25,000 shares bought on each of the last two days of the period at weighted average prices of SEK 54.071024 and SEK 54.425216 respectively. This activity is part of a maximum MSEK 200 program announced on May 28, 2026, running from June 1, 2026, to February 26, 2027, aimed at adjusting capital structure by reducing share capital. Following these repurchases, Synsam held 3,688,635 own shares out of 145,313,746 outstanding shares as of July 24, 2026.
Synsam AB (publ) repurchased a total of 122,000 own shares between July 27 and July 31, 2026. These transactions are part of a share buy-back program announced on May 28, 2026, with a maximum value of MSEK 200, running from June 1, 2026, to February 26, 2027. The program aims to adjust the company’s capital structure by reducing share capital and complies with EU Market Abuse Regulation and Safe Harbour Regulation standards. All repurchases were executed on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ). Following these purchases, Synsam holds 3,810,635 own shares as of July 31, 2026, out of 145,313,746 outstanding shares. Daily volumes ranged from 22,000 to 25,000 shares, with weighted average prices between SEK 55.72 and SEK 57.13.
Synsam AB (publ) will release its interim report for the second quarter of 2026 on Friday, August 21, at 07.30 CEST. The publication includes a comment from President and CEO Håkan Lundstedt and a results presentation by CFO Per Hedblom, available as video materials on the company’s website. Following the report, Synsam will host live webcast Q&A sessions with no pre-registration required. A Swedish-language session is scheduled for 09.30 CEST, while an English-language session will take place at 10.30 CEST. Both sessions feature Lundstedt and Hedblom. Investors, analysts, and media are invited to watch the presentations and participate in the Q&A sessions via the provided webcast links.
Synsam AB (publ) repurchased a total of 104,000 own shares on Nasdaq Stockholm between August 3 and August 7, 2026. The transactions were executed by DNB Carnegie Investment Bank AB (publ) as part of a share buy-back program announced on May 28, 2026, with a maximum value of MSEK 200 running from June 1, 2026, to February 26, 2027. Daily volumes ranged from 20,000 to 22,000 shares, with weighted average prices between SEK 56.024060 and SEK 56.875825. Following these repurchases, Synsam’s holding of own shares amounted to 3,914,635 shares out of 145,313,746 outstanding shares. The program aims to adjust the company’s capital structure by reducing share capital in accordance with EU Market Abuse Regulation and Safe Harbour Regulation requirements.
Synsam AB (publ) repurchased a total of 100,000 of its own shares between August 10 and August 14, 2026. These transactions were executed on Nasdaq Stockholm by DNB Carnegie Investment Bank AB as part of a share buy-back program announced on May 28, 2026. The program, which runs from June 1, 2026, to February 26, 2027, has a maximum value of MSEK 200 and aims to adjust the company’s capital structure by reducing share capital. Daily volumes averaged 20,000 shares with weighted prices ranging from SEK 54.16 to SEK 55.59. Following these purchases, Synsam holds 4,014,635 own shares out of 145,313,746 outstanding shares.
Synsam AB (publ) repurchased a total of 95,000 own shares between August 17 and August 21, 2026. These transactions are part of a share buy-back program announced on May 28, 2026, with a maximum value of MSEK 200, running from June 1, 2026, to February 26, 2027. The repurchases were executed on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ) to adjust the company's capital structure. Daily volumes ranged from 15,000 to 20,000 shares, with weighted average prices between SEK 54.98 and SEK 60.32. Following these purchases, Synsam holds 4,109,635 own shares out of 145,313,746 outstanding shares.
Synsam AB (publ) repurchased a total of 100,000 own shares between August 24 and August 28, 2026. These transactions are part of a share buy-back program announced on May 28, 2026, with a maximum value of MSEK 200, running from June 1, 2026, to February 26, 2027. The repurchases were executed on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ) to adjust the company’s capital structure in compliance with EU Market Abuse Regulation and Safe Harbour Regulation standards. Following these purchases, Synsam holds 4,209,635 own shares out of 145,313,746 outstanding shares. Daily volumes averaged 20,000 shares, with weighted average prices ranging from SEK 59.87 to SEK 58.46 per day.
Synsam Group has secured three finalist positions across two categories in the NCSC Nordic Awards 2026. Synsam Norway competes for Commercial Player of the Year, citing strong growth with SEK 1,365 million in sales and 13.1% organic growth in 2025, alongside the integration of EyeView digital eye examinations. NK Eyewear & Optics in Stockholm and Synsam Vika in Oslo are finalists for Establishment of the Year. NK Eyewear & Optics opened in May 2025 as a luxury concept featuring over 1,400 frames from 35 brands. Synsam Vika, opened on December 19, 2025, is Synsam’s largest Norwegian store at approximately 900 square metres, offering nearly 5,000 pairs of eyewear. Winners will be announced on September 3 in Stockholm.
Synsam AB (publ) repurchased a total of 100,000 own shares between August 31 and September 4, 2026. These transactions form part of a share buy-back program announced on May 28, 2026, with a maximum value of MSEK 200, running from June 1, 2026, to February 26, 2027. The repurchases were executed on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ) to adjust the company’s capital structure. Daily volumes averaged 20,000 shares, with weighted average prices ranging from SEK 56.75 to SEK 58.75. Following these purchases, Synsam holds 4,309,635 own shares out of 145,313,746 outstanding shares.
Synsam Group announced an exclusive collaboration with Swedish artist Carola Häggkvist, naming her a new brand ambassador. The partnership includes the development of a personal sunglasses and eyeglasses collection inspired by Scandinavian design, scheduled for launch in early 2027. This initiative follows Synsam’s earlier collaboration with Erling Haaland and aims to leverage high-profile identities to enhance its exclusive product lines. Design work begins this autumn, with parts of the collection manufactured at Synsam’s production center on Frösön, Sweden. The final products will be available exclusively through Synsam stores across the Nordic region and via the company’s e-commerce platform. Chief Marketing Officer Susanne Westford stated the strategy focuses on combining personal style with Synsam’s expertise in design and eye health.
Synsam AB (publ) repurchased a total of 100,000 own shares between September 7 and September 11, 2026. These transactions are part of a share buy-back program announced on May 28, 2026, with a maximum value of MSEK 200, running from June 1, 2026, to February 26, 2027. The program aims to adjust the company’s capital structure by reducing share capital. All repurchases were executed on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ). Following these purchases, Synsam holds 4,409,635 own shares as of September 11, 2026. The company has 145,313,746 outstanding shares in total.
Synsam AB (publ) repurchased a total of 100,000 own shares between September 14 and September 18, 2026. These transactions occurred on Nasdaq Stockholm via DNB Carnegie Investment Bank AB as part of a share buy-back program announced on May 28, 2026. The program, which runs until February 26, 2027, has a maximum value of MSEK 200 and aims to adjust the company’s capital structure by reducing share capital. Daily volumes were 20,000 shares each day, with weighted average prices ranging from SEK 52.997690 to SEK 54.988690. Following these repurchases, Synsam held 4,509,635 own shares as of September 18, 2026, out of 145,313,746 outstanding shares.
Synsam AB (publ) repurchased a total of 100,000 own shares between September 21 and September 25, 2026. These transactions occurred on Nasdaq Stockholm via DNB Carnegie Investment Bank AB as part of a share buy-back program announced on May 28, 2026. The program has a maximum value of MSEK 200 and runs from June 1, 2026, to February 26, 2027, aiming to adjust the company’s capital structure by reducing share capital. Daily volumes were 20,000 shares each day, with weighted average prices ranging from SEK 53.458515 to SEK 54.091870. Following these repurchases, Synsam held 4,609,635 own shares as of September 25, 2026, out of 145,313,746 outstanding shares.
Ocuco announced a minority investment in Ocumetra, a data science company for eyecare. As part of the deal, Ocuco CEO Leo Mac Canna joined Ocumetra’s board, and Ocumetra’s machine learning tools will integrate with Ocuco’s next-generation cloud-hosted Practice Management Software. Ocumetra offers nine clinical tools, including the Refractogram for myopia treatment efficacy analytics. Founded in 2020 by Professors James Loughman and Ian Flitcroft, the company aims to support eye care professionals with evidence-based decision tools derived from over one million eyes globally. While some products were slated for early 2022 launch, others are classified as software-as-a-medical-device, requiring regulatory approvals such as ISO13485, CE mark, and FDA clearance.
Ocuco announced a rebrand to reflect its shift from single-solution applications to omnichannel native systems. The company retained its name but streamlined the wordmark, maintained its orange color, and replaced purple with black, white, and gradient palettes. This evolution coincides with the prelaunch of Acuitas 3 OmniChannel Edition for enterprise, described as the world’s first cloud-based omnichannel native system for eyecare, featuring telehealth, CRM, and insurance processing. CEO Leo Mac Canna stated the platform removes the need for cumbersome integrations. The rebrand rollout is global over coming weeks, debuting at Vision Expo East 2022. Separately, in September 2025, Ocuco was named one of Ireland’s Best Managed Companies for the eighth time, recognized as a Platinum Requalifying Winner.
In September 2025, Dublin-based eyecare software provider Ocuco appointed Clodagh Nic Canna as Chief Product Officer. Nic Canna previously led the company’s Product Development Department for twelve years and is a member of the Corporate Management Team. CEO Leo Mac Canna stated the appointment supports Ocuco’s transition from an engineering-led to a product-led organization, coinciding with the launch of its cloud-based omnichannel native product and the convergence of existing products into Acuitas 3 OmniChannel. Nic Canna will oversee product vision and strategy across the portfolio. Separately, Ocuco was named one of Ireland’s Best Managed Companies for the eighth time, recognized as a Platinum Requalifying Winner on September 25, 2025.
Ocuco was recognized as a Platinum Requalifying Winner in Ireland’s Best Managed Companies awards on September 25, 2025. This marks the eighth time the company has received this accolade, acknowledging its superior business performance and strategic management. The award follows Deloitte’s evaluation of governance, financial results, culture, and innovation. In 2025, Ocuco continued investing in product development and implemented a responsible AI framework to automate routine tasks. CEO Leo Mac Canna attributed the achievement to employee discipline and customer focus. The broader program recognized 115 indigenous companies with combined turnover exceeding €22 billion.
Ocuco demonstrated its Acuitas 3 OmniChannel Edition software at the 100% Optical event. Director of Product Management Kristian Kiamos explained that the platform provides a unified framework for managing both online and on-site practice operations, distinguishing it from standard practice management systems. Key features highlighted include a comprehensive CRM module for marketing campaigns, business intelligence reporting, and telehealth capabilities via video conferencing. The company emphasized that this omnichannel approach ensures a consistent patient experience across phone, internet, and in-person interactions. This demonstration occurred alongside other recent corporate milestones, including Ocuco’s recognition as an Ireland’s Best Managed Company for the eighth time in September 2025, though the specific focus of the optical trade show presentation remained on the software's operational integration and customer engagement tools.
Ocuco announced a €60 million growth equity investment from Accel-KKR to fuel global expansion and meet rising omnichannel demand in the eyecare industry. The capital will support the scaling of Acuitas 3 OmniChannel Edition, a cloud-based solution designed to integrate online and in-store retail and clinical systems for over 6,750 locations across 88 countries. Additionally, the partnership aims to capitalize on strategic M&A opportunities. This announcement follows Ocuco’s recognition as one of Ireland’s Best Managed Companies for the eighth time in September 2025, highlighting its continued focus on product innovation and responsible AI frameworks.
Editorial relevance: The investment supports Ocuco's expansion of omnichannel eyecare software, addressing the integration of online and in-store retail systems.
Software provider Ocuco announced that retailer Asda has become the inaugural client for its Acuitas 3 OmniChannel Edition, marking a strategic partnership aimed at unifying separate website and practice management systems. Asda Head of Optical Sarah Joyce cited the omnichannel capabilities as key to improving patient and in-store user journeys. Separately, on September 25, 2025, Ocuco was named a Platinum Requalifying Winner in Ireland’s Best Managed Companies awards for the eighth time. The recognition evaluates privately owned businesses on strategy, governance, financial performance, and innovation. Deloitte reported that the 2025 winners include 115 indigenous companies with combined turnover exceeding €22 billion.
Eyecare solutions provider Ocuco was named a Platinum Requalifying Winner at the 17th annual Ireland’s Best Managed Companies awards ceremony held on September 25, 2025, in Dublin. This marks the company’s eighth recognition under the program, which is led by Deloitte Ireland and currently associated with AIB Corporate Banking. The judging process evaluates management teams and business strategies across governance, financial performance, talent, and innovation. In 2025, Ocuco continued investing in product innovation and applied a responsible AI framework to automate routine tasks. CEO Leo Mac Canna attributed the award to employee discipline and focus on eyecare professionals. Deloitte recognized 115 indigenous companies this year, representing 25 of the 32 counties across the island of Ireland.
In September 2025, Dublin-based Ocuco was recognized as a Platinum Requalifying Winner in Ireland’s Best Managed Companies awards. This marks the eighth time the optical software provider has received this distinction from Deloitte. The award follows a rigorous evaluation of management strategy, financial performance, and innovation. Ocuco CEO Leo Mac Canna attributed the success to disciplined execution and continuous improvement in product quality and service levels. The recognition highlights Ocuco’s sustained business performance within the Irish indigenous sector, where 115 companies were honored this year.
Dublin-based eyecare software provider Ocuco announced it has received Service Organization Control 2 (SOC 2 Type II) certification for its Acuitas 3 OmniChannel Edition. Issued by an independent auditor, the certification verifies that Ocuco’s security controls meet stringent criteria for security, availability, processing integrity, confidentiality, and privacy. CEO Leo Mac Canna stated that maintaining such certifications is challenging for in-house systems and older software but essential for large organizations and regulators. Operations Director Peter Furlong noted that achieving this alongside ISO 27001 certification within a single audit cycle reinforces commitment to data protection and opens global market opportunities. The announcement highlights Ocuco’s dedication to safeguarding user data through rigorous risk management and infrastructure alignment.
Ocuco, a Dublin-based optical software provider, appointed Donogh O’Driscoll as its new Chief Financial Officer. Based in the US office, O’Driscoll will lead financial strategy to support global expansion. Separately, Ocuco was named one of Ireland’s Best Managed Companies for the eighth time, receiving Platinum Requalifying status at an awards ceremony on September 25, 2025. The recognition highlights superior business performance, strategic planning, and governance among indigenous Irish firms. In 2025, Ocuco continued investing in product innovation and applied a responsible AI framework to automate routine tasks. CEO Leo Mac Canna attributed the award to employee discipline and customer focus. The broader program recognized 115 companies with combined turnover exceeding €22 billion.
In September 2025, Ocuco was named a Platinum Requalifying Winner in Ireland’s Best Managed Companies awards, marking its eighth recognition. The Dublin-based company received this honor at a ceremony on 25 September for superior business performance and strategic management. This announcement followed Ocuco’s Innovations User Group Meeting held in Clearwater, Florida, from 27–29 March 2025, where over 50 global optical lab professionals explored advancements in Lab Management Software and AI applications. Keynote speakers included Eimear Loughnane of Slalom and Alysse Henkel of The Vision Council. The event featured more than 20 workshops and support from industry partners such as IOT and Schneider Optical Equipment, highlighting Ocuco’s focus on collaborative innovation within the optical lab sector.
Nextech and Ocuco announced a strategic partnership in September 2025 to integrate Ocuco’s Acuitas 3 omnichannel optical software with Nextech’s Ophthalmic Platform. The collaboration aims to bridge clinical excellence and retail performance for ophthalmologists, optometrists, and opticians by managing the full spectrum of care from diagnosis to eyewear sales and inventory. Key benefits include an integrated patient experience, comprehensive practice management combining EHR tools with optical retail capabilities, scalable technology for single or multi-location groups, data-driven insights across clinical and retail operations, and revenue growth opportunities. Both companies committed to providing dedicated support and training for practices adopting the new integration.
Dublin-based optical software provider Ocuco appointed Iarfhlaith Kelly as its new Chief Technology Officer in September 2025. Kelly brings over 20 years of technology leadership experience, including prior CTO roles at Retail inMotion and Matchbook.com, and founding CEO position at Kitman Labs. In his new role, he will lead global technology strategy, focusing on accelerating innovation and integrating emerging technologies like AI into next-generation optical software solutions. The appointment coincides with Ocuco’s recognition as a Platinum Requalifying Winner in Ireland’s Best Managed Companies awards for the eighth time, highlighting the company's continued investment in product innovation and responsible AI frameworks.
Fittingbox and Ocuco announced the renewal of their partnership, originally established in 2018, to deliver digital solutions for eyecare professionals. The collaboration integrates Fittingbox’s virtual try-on technology with Ocuco’s Practice Management, scheduling, and Electronic Medical Records systems. This integration enables customized practice websites that enhance patient experiences while streamlining clinical and retail operations. In a separate development, Ocuco was named one of Ireland’s Best Managed Companies for the eighth time at an awards ceremony on September 25, 2025. Recognized as a Platinum Requalifying Winner, Ocuco highlighted its continued investment in product innovation and responsible AI frameworks during 2025.
Ocuco was recognized as a Platinum Requalifying Winner at the Ireland’s Best Managed Companies awards ceremony on September 25, marking its eighth consecutive win. The Deloitte-led program evaluates privately owned businesses on strategic planning, governance, financial performance, culture, and innovation. In 2025, Ocuco continued investing in product innovation and applied a responsible AI framework to automate routine tasks and streamline internal processes. This year, Deloitte recognized 115 indigenous companies across 25 of Ireland’s 32 counties, with a combined turnover exceeding €22 billion and employment for over 62,000 people. Among requalifying winners, six achieved Platinum Standard status, requiring seven years as a Best Managed Company. CEO Leo Mac Canna attributed the achievement to employee discipline and focus on quality for eyecare professionals.
Ocuco announced a new integration between its optical lab management system, Innovations, and SpecCheck’s digital ordering platform. The partnership enables labs to receive validated Rx orders directly from SpecCheck users, eliminating manual rekeying. It also incorporates SpecCheck’s Lab Pay for secure digital payments and Live Chat for real-time communication between labs and eye care professionals (ECPs). While order processing is available immediately, the rollout of Lab Pay is scheduled for the coming months in a phased approach. This collaboration aims to provide an end-to-end digital experience, enhancing operational efficiency and connectivity within the optical supply chain.
Dublin-based software provider Ocuco announced the appointment of optometrist and technology executive Scott Jens, OD, FAAO, to its Board of Directors in September 2025. The move supports Ocuco’s strategic expansion into the United States eyecare market, specifically targeting independent providers with its cloud-based Acuitas 3 platform. Jens, former CEO of RevolutionEHR and current CEO of Sandbox Spaces, brings experience scaling North American SaaS solutions. His role aims to enhance software integration and feature development for US clinics. Separately, Ocuco was named a Platinum Requalifying Winner in Ireland’s Best Managed Companies awards on September 25, 2025, recognizing its management performance and product innovation over eight consecutive terms.
Mister Spex, a digitally driven omnichannel optician, won the German Sustainability Award in the “Pharmacies and Medical Retail” sector. The award, presented by the Stiftung Deutscher Nachhaltigkeitspreis e.V., recognizes the company’s ecological and social commitments. A jury selected Mister Spex from ten nominees based on publicly available sustainability data. Key initiatives include virtual try-on technology introduced in 2011 to reduce CO2 emissions, a glazing service for existing frames, and sustainable product lines like the 3D-printed EyeD collection and “share x Mister Spex.” The company aims to eliminate single-use plastic by 2025. Co-CEO Mirko Caspar will receive the award at the ceremony held on November 23 in Düsseldorf.
Mister Spex SE reported total revenue of €60 million for Q3 2023, a 2% increase year-on-year. The company achieved positive adjusted EBITDA of €0.2 million (0.4% margin) for the second consecutive quarter. Nine-month revenues grew by 6%, driven by a 10% increase in Germany, while gross margins rose to 49.1%. Adjusted EBITDA for the first nine months reached a profit of €0.9 million, contrasting with a loss in the prior year. Despite headwinds from reduced consumer sentiment and unseasonal weather affecting prescription glasses sales (-3%) and sunglasses growth (+4%), Mister Spex confirmed its full-year 2023 guidance. Management expects mid-to-high single-digit revenue growth and a low single-digit positive adjusted EBITDA margin, supported by efficiency measures and an average order value increase of 10%.